Specifications

ActiGraft is an FDA-cleared regenerative wound care solution that enables health care providers to produce in real-time in vitro blood clot tissue from a patient's whole blood. Once applied, the blood clot tissue serves as a protective covering, biologic scaffold, and wound microenvironment to promote the natural wound healing processes of the body.

ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including but not limited to diabetic/neuropathic ulcers, pressure ulcers/injury, venous stasis ulcers, post-surgical wounds, traumatic wounds, and skin tears.

ActiGraft supports each stage of the wound healing process and delivers significant benefits in terms of comfort, effectiveness, and cost.

Benefits & Features

COST-EFFECTIVE

Covers the wound for long periods of time with minimal care between applications.

EFFICIENT

• 72% of chronic wounds in clinical trials had complete healing within 12 weeks.
• Provides the wound with an optimal, natural healing environment allowing the healing process to proceed unhindered.

SIMPLE

Can be easily prepared at the patient s bedside in 8 minutes and requires no capital equipment.

AUTOLOGOUS

Created from the patient s blood, assuring the safe and effective management of the wound.

EASE OF PAIN

Minimal handling of the wound provides a more comfortable treatment for patients.

---